Three horse-derived antivenoms were tested for their ability to neutralize lethal, hemorrhagic, edema-forming, defibrinating and myotoxic activities induced by the venom of Bothrops atrox from Antioquia and Chocó (Colombia). The following antivenoms were used: a) polyvalent (crotaline) antivenom produced by Instituto Clodomiro Picado (Costa Rica), b) monovalent antibothropic antivenom produced by Instituto Nacional de Salud-INS (Bogotá), and c) a new monovalent anti-B. atrox antivenom produced with the venom of B. atrox from Antioquia and Chocó. The three antivenoms neutralized all toxic activities tested albeit with different potencies. The new monovalent anti-B. atrox antivenom showed the highest neutralizing ability against edema-forming and defibrinating effects of B. atrox venom (41 ± 2 and 100 ± 32 µl antivenom/mg venom, respectively), suggesting that it should be useful in the treatment of B. atrox envenomation in Antioquia and Chocó.
Introduction
Antioquia and Chocó are located in the northwest region of Colombia, a zone with large reserves of tropical rain forest that have allowed the development of an important biodiversity, including 104 snake species (1) . These regions and the Amazonas have the highest incidence of snake bites in Colombia, most of them caused by the abundant species Bothrops atrox, with a death rate of 5% and sequelae in 6% of the patients (2, 3) . This is mainly the result of late arrival at the hospital or, in some cases, of an insufficient antivenom supply or the high cost of lyophilized products. The venom of B. atrox has proteolytic, defibrinating, hemorrhagic, myotoxic, edema-forming and indirect hemolytic activities, with regional differences in venom activities (4) .
These facts prompted us to produce a monovalent anti-B. atrox antivenom specific for the regions of Antioquia and Chocó, and to compare its neutralizing activity against homologous venom with two other crotaline antivenoms available in this region.
Material and Methods

Animals, venom and antivenoms
Webster white mice (18-20 g ) were used for the in vivo experiments. The venom of B. atrox was a pool obtained from 40 specimens collected in Antioquia and Chocó, Colombia, lyophilized and stored at -20 o C until the time for use. One adult horse was immunized at Instituto Clodomiro Picado (Costa Rica) with B. atrox venom from Antioquia and Chocó, using the immunization protocol shown in Table 1 . At the end of the immunization schedule, the horse was bled and plasma was fractionated by ammonium sulfate precipitation (5) .
For comparative purposes in the neutralization experiments, the following two commercially available antivenoms were used: a) the polyvalent (crotaline) antivenom of Instituto Clodomiro Picado (ICP), San José, Costa Rica, batch 2460294 LQ, produced in horses by the same immunization schedule as described above, using a mixture of equal weights of solid venoms of B. asper, Lachesis muta and Crotalus durissus durissus from Costa Rica and, b) the monovalent antibothropic antivenom of Instituto Nacional de Salud (INS), Santafé de Bogotá, batch 140992, produced in horses immunized with B. atrox venom from various regions of Colombia. These two antivenoms were also produced using similar fractionation protocols based on ammonium sulfate precipitation of globulins, without pepsin digestion (5) . Phenol (0.25%) was added as a preservative and the antivenoms were tested before their expiration dates.
Pharmacological activities of B. atrox venom
The minimum edema-forming (MED), hemorrhagic (MHD) and defibrinating (MDD) doses of B. atrox venom were determined by methods described elsewhere (6) (7) (8) , and modified by Gutiérrez et al. (9) (10) (11) . Lethality (lethal dose 50%, LD 50 ) was determined by the Spearman-Karber method (12) using the ip route. Myonecrosis was evaluated by plasma creatine kinase (CK) levels and histologically by determining the myonecrosis index as described by Gutiérrez et al. (13, 14) and Lomonte et al. (15) .
Neutralization assays
The neutralization assays were perfomed by incubating a constant amount of solid venom with various dilutions of antivenom, in order to obtain several antivenom/venom ratios. Incubations were carried out at 37 o C for 30 min and the mixtures were then tested in the corresponding assay systems for each pharmacological activity. The doses of venom selected to test each effect were the following: a) edema: 6 MED = 9 µg; b) hemorrhage: 10 MHD = 16 µg; c) defibrination: 2 MDD = 2.3 µg; d) lethality: 4 LD 50 = 265 µg; e) myonecrosis: 50 µg. Neutralizing ability is reported as effective dose 50% (ED 50 ), defined as the µl antivenom/mg venom ratio that reduces by 50% the activity of venom alone. In the case of neutralization of 
Results
Pharmacological activities of B. atrox venom
The lethal dose 50% of B. atrox venom injected intraperitoneally into mice was 66.2 µg (95% confidence limits: 49.5-88.6). The minimum hemorrhagic dose was 1.6 ± 0.6 µg, the minimum edema-forming dose 1.5 ± 0.3 µg, and the minimum defibrinating dose 1.1 ± 0.3 µg. After im injection of 50 µg of venom, plasma CK levels increased to 664 ± 116 U/ml (control mice injected with saline solution: 60 ± 36 U/ml) and the myonecrosis index was 1.0 (control = 0), confirming the myotoxic effect of the venom. Table 2 shows that the three antivenoms neutralized all pharmacological activities of B. atrox venom studied, albeit with different potencies. Monovalent antibothropic (INS) and monovalent anti-B. atrox antivenoms were equally potent in the neutralization of lethality and hemorrhage, whereas the polyvalent (ICP) antivenom was less efficient in the neutralization of these effects. Regarding edema and defibrination, the monovalent anti-B. atrox antivenom showed the highest neutralizing ability. No significant differences were observed between the three antivenoms concerning neutralization of myonecrosis (Table 2) .
Neutralization of venom activities
Discussion
The parenteral administration of horseor sheep-derived antivenoms constitutes the cornerstone in the treatment of snakebite envenomation (16) . Since venoms present Table 2 -Neutralization of pharmacological activities of B. atrox venom from Antioquia and Chocó by the three antivenoms.
Neutralization is reported as effective dose 50% for lethal, hemorrhagic, edema-forming and myonecrotic effects and as effective dose 100% for the defibrinating effect (see Material and Methods). (20) .
On the other hand, when the effective doses 50% of these antivenoms were compared, the monovalent anti-B. atrox antivenom produced with venoms from Antioquia and Chocó showed the highest neutralizing ability against the venom of B. atrox from these regions.
Local tissue damage (myonecrosis, hemorrhage and edema) is one of the most typical and dangerous consequences of B. atrox envenomation in Colombia (2). These effects result in severe lesions and, in a number of cases, in sequelae (2,3). The rapid development of these local effects makes efficient neutralization by antivenoms difficult (9) (10) (11) . Thus, it is necessary to have antivenoms with high neutralizing capacity against the toxins responsible for these effects in order to reduce the local tissue damage.
Our results indicate that the three antivenoms were similarly efficient in neutralizing myonecrosis, whereas monovalent anti-B. atrox antivenom had the highest neutralizing ability against the edema-forming effect. Regarding hemorrhage, monovalent anti-B. atrox and monovalent antibothropic (INS) antivenoms were more potent than polyvalent antivenom, although all three neutralized this effect at a low antivenom/venom ratio.
In conclusion, the three antivenoms tested are efficient in neutralizing the most relevant toxic effects induced by the venom of B. atrox from Antioquia and Chocó. The monovalent antivenom produced with venoms from specimens collected in these regions in Colombia showed the highest neutralizing potency. We suggest that this antivenom may be of high value in the treatment of B. atrox envenomation in Antioquia and Chocó. A randomized clinical trial is currently under way in Colombia in order to test this hypothesis.
